Share This

Create Your Own Business Intelligence Website   Input the stock code or the company name     Search   <00512.HK> - Grand Pharmaceutical Group Limited    Stock Screener：Medicine, Pharmaceuticals HUTCHMED C.P. POKPHAND PAK FAH YEOW ALI HEALTH SIPAI HEALTH OCI INTL INNOVATIVE PHAR WANJIA GROUP TIANDA PHARMA SIHUAN PHARM LANSEN PHARMA TRAD CHI MED PASHUN INT'L REGENT PACIFIC CONCH ENVIRO UNI-BIO GROUP SHANDONG XINHUA CKLIFE SCIENCES EXTRAWELL PHAR CMS BAIYUNSHAN PH WAI YUEN TONG ZHONG JIA GX QIANHAI HEALTH SHUNTEN INTL C ANIMAL HEALTH LEE'S PHARM NT PHARMA ESSEX BIO-TECH CSPC PHARMA SINOPHARM KINGWORLD CMBC CAPITAL CGN MINING SINO BIOPHARM KONTA CHINA SH PIONEER HLDG OCUMENSION-B PURAPHARM LIVZON PHARMA FRONTAGE 3SBIO HEC CJ PHARM MODERN CHI MED FUSEN PHARM TONG REN TANG CONSUN PHARMA CIRC SANAI HEALTH GP SSY GROUP SIMCERE PHARMA JBM HEALTHCARE LUYE PHARMA FOSUN PHARMA UNI HEALTH CHARMACY PHAR BIOCYTOGEN-B DAWNRAYS PHARMA WUXI APPTEC HUA MEDICINE-B SH PHARMA JACOBSON PHARMA SHINEWAY PHARM LONGRUN TEA CHINARES PHARMA SINOLIFE UTD TYCOON GROUP TONGRENTANGCM HANSOH PHARMA ZHONGZHIPHARM PHARMARON UNITED LAB NEW RAY MEDIC JOINN JD HEALTH ZHAOKE OPHTH-B AIM VACCINE ASYMCHEM SINCO PHARMA HINSANG GROUP GOLDEN THROAT HAO WEN HLDGS CB GLOBAL CH BIOTECH SER JILIN CHANGLONG CH DEMETER FIN GF HEALTHCARE CRMI BAYTACARE PHARM C HEALTH GP SILK RD ENERGY NEP INTERLONG LARRY JEWELRY    Basic Datum Company name Lot P/E P/B EPS DPS GRAND PHARMA 500 7.63 0.9344 0.536 0.26 Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend    Related links    Related news    遠大醫藥取得創新眼用製劑 「TP-03」大中華區獨家授權 首...   遠大醫藥治療胃腸胰腺神經內分泌腫瘤新藥獲批內地三期臨床   《公司業績》遠大醫藥全年純利18.8億元跌9.6% 派末期息...   遠大醫藥用於延緩兒童近視新藥臨床試驗獲批   遠大醫藥合作夥伴滴眼液新藥上市申請獲美國FDA批准   遠大醫藥集團授出逾2.2億港元可換股借款  ≫More    Company Rating Date Broker Company name Rating Target ≫More    Company performance - Published Date Company name Turnover* Profit* % Dividend ≫More    Comment 2024-03-26　遠大醫藥３月２４日晚公告稱，公司用於治療胃腸胰腺神經內分泌瘤（ＧＥＰ-ＮＥＴＳ）的全球創新放射性核素偶聯藥物ＩＴＭ-１１近日已得到國家藥監局批准開展ＩＩＩ期臨床研究（ＣＯＭＰＯＳＥ研究）。   2024-03-26　值得注意的是，ＣＯＭＰＯＳＥ研究是一項國際多中心ＩＩＩ期臨床研究，中國臨床的加入，一方面將大幅推進ＩＴＭ-１１在中國的注冊研發工作，另一方面也進一步增長了遠大醫藥在核藥抗腫瘤診療領域臨床開發工作國際化程度。如今，遠大醫藥已成為進入中國ＩＩＩ期臨床研究的診斷和治療類ＲＤＣ創新藥儲備最多的企業，也是全球核藥抗腫瘤領域擁有最豐富產品管線和診療一體化布局的創新藥企之一。   2024-04-02　就國內核藥市場布局來說，遠大醫藥集團有限公司（簡稱遠大醫藥，０５１２．ＨＫ）可謂領頭羊。就核藥抗腫瘤診療板塊，遠大醫藥已儲備１４款創新產品，涵蓋６８ＧＡ、１７７ＬＵ、１３１Ｉ、９０Ｙ、８９ＺＲ、９９ＭＴＣ在內的６種放射性核素，覆蓋了肝癌、前列腺癌、腦癌等在內的７個癌種，是我國布局最多的藥企之一。   2024-04-16　位於黃石市陽新縣富池鎮的遠大醫藥富池工業園，誕生了全球排名第一的牛磺酸生產企業、全球第一的甲硝唑和安乃近的原料生產企業、全球第一的小品種氨基酸生產企業，成為遠大醫藥提升最快、收入最穩定、出口創匯最多的基地。   2024-04-23　遠大醫藥集團有限公司（簡稱遠大醫藥，０５１２．ＨＫ）發展態勢維持穩中向好，多個核心業務板塊的創新布局持續得到主要發展，企業綜合實力不斷增長。   2024-04-23　溫江企業在ＡＤＣ領域大放異彩、在ＲＤＣ領域初具規模，科倫博泰、百利天恆相繼刷新中國創新藥對外授權交易新紀錄，遠大醫藥斥資百億收購的釔-９０微球注射液及核藥版塊全部落戶溫江，通瑞生物、艾博茲、輻聯醫藥等一批新型ＲＤＣ企業相繼落地，溫江醫藥健康產業正以前所未有的速度蓬勃發展，得到行業高度關注，也成為了未來ＸＤＣ新藥大會的首倡者。   2024-04-23　遠大醫藥集團有限公司為香港上市公司（簡稱：遠大醫藥，代碼：０５１２．ＨＫ），是一家科技創新型國際化醫藥企業，核心業務橫跨制藥科技、核藥抗腫瘤診療及心腦血管精准介入診療科技、生物科技三大領域。   2024-04-23　中國網財經記者注意到，小方制藥核心產品開塞露近年來市場占有率或大幅下降，開塞露藥品市場競爭格局亦發生較大變化。２０１８年６月，港股上市公司遠大醫藥公布公告指出，擬以１５．５億元人幣的價錢收購上海運佳黃浦制藥有限公司１００％股份。      Top Gain / Loss Show All Charts     Value Name Updated Value Change Change % HSI 04-22 09:30 16513.6 ▲ 289.41 ▲ 1.78% GRAND PHARMA 04-23 16:09 3.99 ▲ 3.99 ▲ ∞% ≫More

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.